Serum miRNA-186-3P and miRNA-382-3P constitute a novel Diagnostic miRNA signature for palindromic rheumatism.

IF 5.7 2区医学 Q1 IMMUNOLOGY

Frontiers in Immunology Pub Date : 2025-03-24 eCollection Date: 2025-01-01 DOI:10.3389/fimmu.2025.1569846

Fangfang Yuan, Zefu Weng, Qiong Yang, Jing Luo, Lina Ying, Haiyan Huang, Xin Zhang, Yahui Chen, Jixia Lin, Junhong He

{"title":"Serum miRNA-186-3P and miRNA-382-3P constitute a novel Diagnostic miRNA signature for palindromic rheumatism.","authors":"Fangfang Yuan, Zefu Weng, Qiong Yang, Jing Luo, Lina Ying, Haiyan Huang, Xin Zhang, Yahui Chen, Jixia Lin, Junhong He","doi":"10.3389/fimmu.2025.1569846","DOIUrl":null,"url":null,"abstract":"Background: Palindromic rheumatism (PR) is a unique disease characterized by the intermittent inflammation of different joints that may progress to a variety of immune-related diseases. Unclear diagnostic criteria have limited the research on its pathogenesis and treatment options. Recently, microRNAs (miRNAs) have been used in the diagnosis of various diseases; however, the role of miRNAs in PR diagnosis remains unexplored. Using next-generation high-throughput sequencing (NGS), this study aimed to screen miRNAs specifically expressed in the serum of patients with PR to construct a miRNA signature and verify its diagnostic efficacy.Methods: Patients with PR (N=4), patients with rheumatoid arthritis (RA; N=3), and healthy individuals (Con; N=3) were included in an exploration cohort. Differentially expressed miRNAs were screened using NGS to construct a miRNA signature, and bioinformatics tools were used to perform target gene enrichment analysis of the top 25 differentially expressed miRNAs, both upregulated and downregulated. RT-qPCR was used to verify the differential expression of the miRNA signature in three validation cohorts of patients with PR (N=27) and RA (N=30), and healthy individuals (N=31). The efficiency of the miRNA signature was evaluated using receiver operator characteristic (ROC) curves, an analytical method that assesses diagnostic accuracy.Results: A total of 130 miRNAs were differentially expressed in the PR exploration cohort, including 35 upregulated and 95 downregulated compared to levels in the RA and healthy cohorts. miRNA-186-3p showed the largest upregulated difference and miRNA-382-3p the largest downregulated difference; these were selected to construct the miRNA signature. In the ROC curve of the validation cohort, the PR miRNA signature produced an area under the ROC curve (AUC) of 0.980 (95% CI 0.942-1.000) when distinguishing from healthy individuals and of 0.906 (95% CI 0.830-0.983) when distinguishing from RA patients. However, miRNA-186-3p and miRNA-382-3p levels were not associated with disease activity in patients with PR.Conclusion: A miRNA signature comprising miRNA-186-3p and miRNA-382-3p can effectively diagnose and differentiate PR from RA. This study provides a basis for the creation of a clinical miRNA signature for the diagnosis of PR.","PeriodicalId":12622,"journal":{"name":"Frontiers in Immunology","volume":"16 ","pages":"1569846"},"PeriodicalIF":5.7000,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973322/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fimmu.2025.1569846","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Palindromic rheumatism (PR) is a unique disease characterized by the intermittent inflammation of different joints that may progress to a variety of immune-related diseases. Unclear diagnostic criteria have limited the research on its pathogenesis and treatment options. Recently, microRNAs (miRNAs) have been used in the diagnosis of various diseases; however, the role of miRNAs in PR diagnosis remains unexplored. Using next-generation high-throughput sequencing (NGS), this study aimed to screen miRNAs specifically expressed in the serum of patients with PR to construct a miRNA signature and verify its diagnostic efficacy.

Methods: Patients with PR (N=4), patients with rheumatoid arthritis (RA; N=3), and healthy individuals (Con; N=3) were included in an exploration cohort. Differentially expressed miRNAs were screened using NGS to construct a miRNA signature, and bioinformatics tools were used to perform target gene enrichment analysis of the top 25 differentially expressed miRNAs, both upregulated and downregulated. RT-qPCR was used to verify the differential expression of the miRNA signature in three validation cohorts of patients with PR (N=27) and RA (N=30), and healthy individuals (N=31). The efficiency of the miRNA signature was evaluated using receiver operator characteristic (ROC) curves, an analytical method that assesses diagnostic accuracy.

Results: A total of 130 miRNAs were differentially expressed in the PR exploration cohort, including 35 upregulated and 95 downregulated compared to levels in the RA and healthy cohorts. miRNA-186-3p showed the largest upregulated difference and miRNA-382-3p the largest downregulated difference; these were selected to construct the miRNA signature. In the ROC curve of the validation cohort, the PR miRNA signature produced an area under the ROC curve (AUC) of 0.980 (95% CI 0.942-1.000) when distinguishing from healthy individuals and of 0.906 (95% CI 0.830-0.983) when distinguishing from RA patients. However, miRNA-186-3p and miRNA-382-3p levels were not associated with disease activity in patients with PR.

Conclusion: A miRNA signature comprising miRNA-186-3p and miRNA-382-3p can effectively diagnose and differentiate PR from RA. This study provides a basis for the creation of a clinical miRNA signature for the diagnosis of PR.

查看原文本刊更多论文

血清miRNA-186- 3p和miRNA-382- 3p构成了一种新的复发性风湿病诊断miRNA特征。

背景：复发性风湿病（parindromic rheumatism， PR）是一种以不同关节间歇性炎症为特征的独特疾病，可发展为多种免疫相关疾病。不明确的诊断标准限制了其发病机制和治疗选择的研究。近年来，microRNAs （miRNAs）已被用于各种疾病的诊断；然而，mirna在PR诊断中的作用仍未被探索。本研究利用新一代高通量测序技术（NGS）筛选PR患者血清中特异性表达的miRNA，构建miRNA特征，验证其诊断效果。方法：PR患者（N=4）、类风湿性关节炎患者(RA；N=3)，健康个体(Con；N=3)被纳入一个探索队列。通过NGS筛选差异表达的miRNA，构建miRNA特征，并利用生物信息学工具对前25个差异表达的miRNA进行靶基因富集分析，包括上调和下调的miRNA。RT-qPCR验证了PR患者（N=27）、RA患者（N=30）和健康个体（N=31）三个验证队列中miRNA特征的差异表达。使用receiver operator characteristic （ROC）曲线（一种评估诊断准确性的分析方法）来评估miRNA标记的效率。结果：与RA和健康队列相比，PR探索队列中共有130个mirna差异表达，其中35个表达上调，95个表达下调。miRNA-186-3p上调差异最大，miRNA-382-3p下调差异最大；这些被选中构建miRNA签名。在验证队列的ROC曲线中，PR miRNA特征与健康个体的ROC曲线下面积（AUC）为0.980 (95% CI 0.942-1.000)，与RA患者的ROC曲线下面积（AUC）为0.906 （95% CI 0.830-0.983）。结论：由miRNA-186-3p和miRNA-382-3p组成的miRNA特征可以有效地诊断和鉴别PR与RA。本研究为PR临床诊断miRNA标记的建立提供了基础。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Immunology IMMUNOLOGY-

CiteScore

9.80

自引率

11.00%

发文量

7153

审稿时长

14 weeks

期刊介绍： Frontiers in Immunology is a leading journal in its field, publishing rigorously peer-reviewed research across basic, translational and clinical immunology. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. Frontiers in Immunology is the official Journal of the International Union of Immunological Societies (IUIS). Encompassing the entire field of Immunology, this journal welcomes papers that investigate basic mechanisms of immune system development and function, with a particular emphasis given to the description of the clinical and immunological phenotype of human immune disorders, and on the definition of their molecular basis.